Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Children With Relapsed/Refractory Solid Tumors
NCT02444884Phase 1Completed
- Sponsor
- Children's Oncology Group
- Start
- Sep 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of alisertib in solid tumor and neuroblastoma (3 arms), sponsored by Children's Oncology Group. Primary endpoints: Maximum Tolerated Dose and Recommended Phase II Dose (Once Daily) up to 21 days, Maximum Tolerated Dose and Recommended Phase II Dose (Twice Daily) up to 21 days and 2 more. Started Sep 2008; status: completed.
02
Drugs
alisertib
03
Conditions
solid tumorneuroblastoma
Beyond the preview
Go deeper on NCT02444884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444884.